For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of dopaminergic neurons in the substantia nigra is well recognized and drives ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...